Review
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 10, 2017; 8(4): 305-319
Published online Aug 10, 2017. doi: 10.5306/wjco.v8.i4.305
Magnetic resonance imaging for prostate cancer before radical and salvage radiotherapy: What radiation oncologists need to know
Felipe Couñago, Gemma Sancho, Violeta Catalá, Diana Hernández, Manuel Recio, Sara Montemuiño, Jhonathan Alejandro Hernández, Antonio Maldonado, Elia del Cerro
Felipe Couñago, Elia del Cerro, Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, 28223 Madrid, Spain
Felipe Couñago, Elia del Cerro, Clinical Department, Faculty of Biomedicine, Universidad Europea, 28670 Madrid, Spain
Gemma Sancho, Department of Radiation Oncology, Hospital de la Santa Creu i Sant Pau, 08026 Barcelona, Spain
Violeta Catalá, Jhonathan Alejandro Hernández, Department of Radiology, Fundació Puigvert, 08025 Barcelona, Spain
Diana Hernández, Department of Radiology, Hospital de la Santa Creu i Sant Pau, 08026 Barcelona, Spain
Manuel Recio, Department of Radiology, Hospital Universitario Quirónsalud Madrid, 28223 Madrid, Spain
Sara Montemuiño, Department of Radiation Oncology, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
Antonio Maldonado, Department of Nuclear Medicine, Hospital Universitario Quirónsalud Madrid, 28223 Madrid, Spain
Author contributions: All authors contributed to this manuscript.
Conflict-of-interest statement: Authors declare no conflicts of interest for this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Felipe Couñago, MD, Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, Calle Diego de Velázquez 1, Pozuelo de Alarcón, 28223 Madrid, Spain. felipe.counago@quironsalud.es
Telephone: +34-676-839746
Received: January 26, 2017
Peer-review started: February 8, 2017
First decision: March 27, 2017
Revised: March 30, 2017
Accepted: June 12, 2017
Article in press: June 13, 2017
Published online: August 10, 2017
Processing time: 193 Days and 5.4 Hours
Core Tip

Core tip: Multiparametric magnetic resonance imaging (mpMRI) has revolutionized the management of prostate cancer, including external beam radiotherapy (EBRT). mpMRI has also improved local staging and recurrence detection after radical prostatectomy, even in patients with low prostate-specific antigen levels, and it has increased the accuracy of EBRT, potentially improving survival outcomes while reducing side effects. For these reasons, mpMRI is an essential tool in the evaluation and treatment of prostate cancer.